Trial record 2 of 186 for:
Quantification of Upper Extremity Hypertonia
This study has been completed.
Information provided by (Responsible Party):
Terence Sanger, University of Southern California
First received: January 31, 2006
Last updated: March 11, 2013
Last verified: March 2013
Dr. Sanger and the research team want to learn about upper extremity hypertonia (stiffness) in children and young adults with cerebral palsy. Specifically, they want to learn about ways to measure the stiffness in the joints of hypertonic arms. The information the research team will collect includes any physical exams or computer generated data about your arm movements.
||Time Perspective: Prospective
||Quantification of Upper Extremity Hypertonia
Primary Outcome Measures:
- Observation [ Time Frame: 1 hour ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||December 2012 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||4 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Children with cerebral palsy and/or dystonia.
Inclusion Criteria:Dystonia in at least one arm Age 4 to no upper limit
Exclusion Criteria:increased risk of participation botulinum toxin within 6 months
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00285870
|Stanford University School of Medicine
|Stanford, California, United States, 94305 |
University of Southern California
||Terence D. Sanger
No publications provided
||Terence Sanger, Associate Professor, University of Southern California
History of Changes
|Other Study ID Numbers:
||UPPER EXTREMITY HYPERTONIA
|Study First Received:
||January 31, 2006
||March 11, 2013
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 21, 2015
Nervous System Diseases
Signs and Symptoms